The Pink Pill Documentary Exposes Medical Bias Against Female Sexual Desire
The documentary The Pink Pill: Sex, Drugs & Who Has Control reveals a troubling reality within the pharmaceutical industry and medical establishment regarding female sexual health. The film chronicles the decade-long battle to gain approval for flibanserin, a drug designed to treat low female libido, which faced significantly more regulatory hurdles than comparable medications for men.
A Revolutionary Drug Meets Resistance
Barbara Gattuso, a happily married woman for decades, experienced what she describes as a mysterious evaporation of her sexual desire during perimenopause. "It was like somebody pulled the plug," she recalls in the documentary. Her participation in a clinical trial for flibanserin in the late 2000s offered hope, with Dr. Irwin Goldstein, a key consultant on Viagra, documenting her transformation into feeling "phenomenal" and like a "new woman."
Originally developed as an antidepressant by German company Boehringer Ingelheim, flibanserin showed unexpected promise for treating Hypoactive Sexual Desire Disorder (HSDD) in women by working on neurotransmitters in the brain's "sex center." Despite this potential, the drug faced what director Aisling Chin-Yee describes as "regulatory roadblocks, pharmaceutical price-gouging, sexist double standards and a profound societal disinterest in female choice, pleasure and experience."
Medical Establishment's Paternalistic Attitude
The documentary exposes how female sexual health remains marginalized within medical education and practice. Most medical school curricula lack comprehensive sections on female sexual health, libido, or clitoral anatomy. This institutional gap created what Dr. Anita Clayton, a University of Virginia psychiatrist and Addyi consultant, calls "a very paternalistic attitude" during FDA review.
When pharmaceutical entrepreneur Cindy Eckert purchased flibanserin for $5 million in 2011 after Boehringer Ingelheim abandoned FDA approval efforts, she renamed the drug Addyi and formed Sprout Pharmaceuticals to complete necessary trials. Despite demonstrating improved sexual drive and experiences for women with HSDD, the FDA assigned its review to the urology division—an odd fit for a drug working on brain neurotransmitters rather than physical blood flow.
Double Standards in Drug Approval
The FDA's questioning of Addyi revealed stark gender biases in pharmaceutical regulation. Agency officials expressed concern that "a woman might take flibanserin the night before and get up the next morning and fall asleep taking her kids to school," according to Dr. Clayton's recollection in the film. Data showing an increase of one "successful sexual event" per month was dismissed as ineffective, despite women with untreated HSDD experiencing only one or two such events annually.
"That's not a question that has ever come up when it comes to male sexual dysfunction," noted Chin-Yee. "It is absolutely imperative that if you are a man with a penis, you should be able to do whatever you want with it. And those were not the same considerations for women."
Cultural Backlash and Personal Toll
The film documents the cultural wars surrounding what critics derisively called "the female Viagra." Late-night television hosts joked about the medication, while some medical professionals questioned whether HSDD represented a legitimate condition or simply pharmaceutical profiteering from normal variations in female desire.
For women experiencing HSDD, the lack of options proved devastating. One patient described feeling "like someone had slayed me" when menopause eliminated her formerly steady libido. Another expressed frustration with societal expectations that "you're a mother now and you focus on these things. That's behind you." Both Gattuso and her daughter testified emotionally at FDA hearings about the toll diminished libido had taken on their lives.
A Pyrrhic Victory with Major Caveats
After intense lobbying, the FDA approved Addyi in August 2015 for premenopausal women with HSDD (extending to postmenopausal women in December 2022). However, the victory came with significant restrictions: a black box warning for side effects including dizziness, nausea, and headache; mandatory testing for prescribing doctors and pharmacists; and a requirement that patients sign pledges to avoid alcohol entirely.
Eckert sold Sprout Pharmaceuticals to Valeant for $1 billion following approval, but the pharmaceutical giant subsequently doubled Addyi's price to $800 per prescription before shelving the drug entirely in 2017. "How can you possibly pass something that is so wonderful for women and then have it ripped out?" asks Gattuso in the film. "After all of this work, all of this emotion, we're down to square one again."
The Ongoing Struggle for Choice
Eckert eventually repurchased Addyi from Valeant and returned it to market, though online searches still prominently display warnings about side effects. The documentary highlights the stark contrast between treatment options for male and female sexual dysfunction: 26 approved drugs exist for men, while women face continued skepticism about whether sexual pleasure justifies potential medication risks.
"You should be able to have that discussion with your own body and your own physician, rather than somebody just removing it as an option for you," emphasizes Chin-Yee. The film connects this struggle to broader issues of bodily autonomy in a post-Roe America, where reproductive rights face increasing restrictions.
"You might think it's funny and frivolous to say that women enjoying sex with their husbands is necessary," concludes Chin-Yee. "But it is exactly that right being taken away that is related to all the other rights that could be taken away from you, and are being removed in the United States right now."
The Pink Pill presents a compelling case that female sexual health deserves the same serious consideration as male sexual health within medical research, pharmaceutical development, and regulatory approval processes. The documentary is currently available for streaming on Paramount+.
